Crinetics Pharmaceuticals (CRNX) News Today $29.66 -0.12 (-0.40%) Closing price 04:00 PM EasternExtended Trading$29.66 0.00 (-0.02%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Rep. Josh Gottheimer Sells Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockRepresentative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred iApril 15 at 8:00 PM | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P.Alliancebernstein L.P. increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 101,720 shares of the company's stock afterApril 15 at 3:57 AM | marketbeat.comJPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)JPMorgan Chase & Co. reduced its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 269,543 shares of the companApril 14 at 3:29 AM | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Moderate Buy" from AnalystsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and twelve have assigned a buyApril 14 at 3:20 AM | marketbeat.comFmr LLC Acquires 4,472,316 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Fmr LLC raised its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 100.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,928,086 shares of the company's stock after purchasing anApril 12 at 5:42 AM | marketbeat.comGeode Capital Management LLC Boosts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Geode Capital Management LLC increased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 13.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,098,841 sharApril 12 at 4:39 AM | marketbeat.comCrinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025April 11, 2025 | globenewswire.comCrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2025 | globenewswire.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week Low - Here's What HappenedCrinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year Low - Here's WhyApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Has $2.72 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)ADAR1 Capital Management LLC lessened its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 39.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 53,125 shares of the company's stock after selling 35,300 shares during the quApril 9, 2025 | marketbeat.comSchroder Investment Management Group Makes New $1.49 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Schroder Investment Management Group purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 29,361 shares of the company's stock, valued atApril 8, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Cinctive Capital Management LPCinctive Capital Management LP trimmed its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 25.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,988 shares of the compApril 5, 2025 | marketbeat.comBryce Point Capital LLC Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Bryce Point Capital LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 22,686 shares of the company's stock, valued at approximately $1,1April 5, 2025 | marketbeat.comFranklin Resources Inc. Raises Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Franklin Resources Inc. lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,591,666 shares of the compApril 5, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 4.3% - Should You Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3% - Time to Sell?April 3, 2025 | marketbeat.comWellington Management Group LLP Raises Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Wellington Management Group LLP boosted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 55.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,950,567 shares of the cApril 3, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company's stock after acquiring an adApril 3, 2025 | marketbeat.comCrinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFAApril 2, 2025 | seekingalpha.com16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning ASKLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company's stock, valued at approximately $818,000. A number ofApril 2, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year Low - Should You Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year Low - What's Next?April 1, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Pictet Asset Management Holding SAPictet Asset Management Holding SA decreased its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 848,050 shares of the company's stock after selling 60April 1, 2025 | marketbeat.comAmerican Century Companies Inc. Boosts Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)American Century Companies Inc. lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 477,298 shares of the company's stoMarch 31, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Prudential Financial Inc.Prudential Financial Inc. increased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 60.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 277,370 shares of the company's stock after purchasingMarch 29, 2025 | marketbeat.comCrinetics gets EMA approval for paltusotine marketing authorization applicationMarch 28, 2025 | markets.businessinsider.com150,398 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Acquired by Segall Bryant & Hamill LLCSegall Bryant & Hamill LLC purchased a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 150,398 shares of the company's stock, valued at appMarch 28, 2025 | marketbeat.comCrinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in AcromegalyMarch 27, 2025 | globenewswire.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 6.1% - Time to Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 6.1% - Here's What HappenedMarch 27, 2025 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Stifel NicolausStifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals in a report on Tuesday. They issued a "buy" rating and a $60.00 price target for the company.March 26, 2025 | marketbeat.comStifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy RecommendationMarch 25, 2025 | msn.com8,206 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by Cibc World Markets CorpCibc World Markets Corp acquired a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 8,206 shares of the company's stock, valued aMarch 24, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Connor Clark & Lunn Investment Management Ltd. cut its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 66.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,898 shares of the company's sMarch 24, 2025 | marketbeat.comSwiss National Bank Purchases 28,500 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Swiss National Bank lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 21.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 159,400 shares of the company's stock after acquiring an additionalMarch 23, 2025 | marketbeat.comProficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Proficio Capital Partners LLC purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 14,674 shares of the company's stock, valued at approximately $750March 23, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 2,515 SharesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 2,515 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $34.20, for a total value of $86,013.00. Following the sale, the insider now directly owns 72,233 shares in the company, valued at approximately $2,470,368.60. This represents a 3.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 22, 2025 | marketbeat.comJeff E. Knight Sells 7,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) COO Jeff E. Knight sold 7,162 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total transaction of $244,940.40. Following the sale, the chief operating officer now owns 87,491 shares in the company, valued at $2,992,192.20. The trade was a 7.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.March 22, 2025 | marketbeat.comRichard Scott Struthers Sells 17,338 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) CEO Richard Scott Struthers sold 17,338 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $34.20, for a total value of $592,959.60. Following the transaction, the chief executive officer now directly owns 329,147 shares in the company, valued at $11,256,827.40. The trade was a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.March 22, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 2,515 SharesMarch 22, 2025 | insidertrades.comIntech Investment Management LLC Has $2.20 Million Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Intech Investment Management LLC lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 92.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,105 shares of the company's stocMarch 22, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from BrokeragesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buyMarch 19, 2025 | marketbeat.com18,117 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 18,117 shares of the company's stock, valued at approximatelyMarch 18, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 15.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 759,126 shares of the company's stock after buyinMarch 16, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. decreased its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 18.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 281,451 shares of the comMarch 13, 2025 | marketbeat.comBank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Bank of New York Mellon Corp lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 344,765 shares ofMarch 12, 2025 | marketbeat.comCrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 10, 2025 | globenewswire.comProficio Capital Partners LLC Acquires Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Proficio Capital Partners LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,674 shares of the company's stock, valued atMarch 9, 2025 | marketbeat.comLisanti Capital Growth LLC Sells 25,875 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Lisanti Capital Growth LLC cut its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 23.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 82,700 shares of the company's stock after selling 25,87March 8, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | insidermonkey.comFisher Asset Management LLC Boosts Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Fisher Asset Management LLC lifted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 559,287 shares of the company's stock aftMarch 3, 2025 | marketbeat.com Remove Ads Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼1.030.80▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼126▲CRNX Articles Average Week Remove Ads Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Qiagen News Today Viatris News Today Roivant Sciences News Today Lantheus News Today Revolution Medicines News Today BridgeBio Pharma News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRNX Stock Free CRNX Stock Alerts